Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.38 +0.8%	$17.77	$13.50 ▼ $25.67	$4.12B	0.38	3.41 million shs	2.10 million shs
PCVX Vaxcyte	$30.77 +0.7%	$33.44	$27.66 ▼ $121.06	$3.97B	1.21	1.52 million shs	1.32 million shs
STOK Stoke Therapeutics	$19.77 +2.4%	$13.77	$5.35 ▼ $19.97	$1.06B	1.15	918,418 shs	684,000 shs
TLX Telix Pharmaceuticals	$10.15 -16.1%	$14.07	$9.80 ▼ $30.36	$4.09B	N/A	133,195 shs	1.29 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+0.88%	-0.29%	-4.17%	-12.75%	-0.58%
PCVX Vaxcyte	+0.99%	-2.27%	-14.83%	-6.86%	-61.22%
STOK Stoke Therapeutics	-0.36%	-0.10%	+50.66%	+98.36%	+39.15%
TLX Telix Pharmaceuticals	-3.51%	+10.30%	-13.32%	-26.35%	+1,209,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.3447 of 5 stars	3.7	3.0	0.0	0.0	3.6	2.5	3.1
PCVX Vaxcyte	2.3939 of 5 stars	3.5	2.0	0.0	0.0	3.5	1.7	0.0
STOK Stoke Therapeutics	4.4774 of 5 stars	4.6	1.0	0.0	4.8	2.1	0.8	1.3
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	59.19% Upside
PCVX Vaxcyte	3.09	Buy	$136.50	343.61% Upside
STOK Stoke Therapeutics	3.22	Buy	$25.57	29.34% Upside
TLX Telix Pharmaceuticals	2.80	Moderate Buy	$22.33	120.03% Upside

Current Analyst Ratings Breakdown

Latest STOK, ADMA, TLX, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	TLX Telix Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
8/28/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
8/18/2025	STOK Stoke Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$28.00
8/13/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
8/7/2025	PCVX Vaxcyte	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.73	$0.55 per share	31.87	$1.67 per share	10.41
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$23.66 per share	N/A
STOK Stoke Therapeutics	$36.56M	29.63	N/A	N/A	$6.11 per share	3.24
TLX Telix Pharmaceuticals	$516.72M	6.65	$0.10 per share	105.96	$1.12 per share	9.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.86	20.21	25.19	N/A	44.06%	41.01%	28.47%	11/6/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$4.11	0.00	N/A	N/A	N/A	-16.85%	-15.92%	11/4/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.85	22.71	N/A	N/A	26.25%	18.32%	15.48%	11/4/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	21.15	N/A	N/A	N/A	N/A	N/A

Latest STOK, ADMA, TLX, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	$31.51 million	$13.82 million
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million
8/6/2025	Q2 2025	PCVX Vaxcyte	-$1.12	-$1.22	-$0.10	-$1.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.21	5.33	2.78
PCVX Vaxcyte	N/A	11.11	11.11
STOK Stoke Therapeutics	N/A	6.98	6.98
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
PCVX Vaxcyte	96.78%
STOK Stoke Therapeutics	N/A
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
PCVX Vaxcyte	3.10%
STOK Stoke Therapeutics	9.50%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.63 million	230.28 million	Optionable
PCVX Vaxcyte	160	129.82 million	125.80 million	Optionable
STOK Stoke Therapeutics	100	54.80 million	49.59 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A

STOK, ADMA, TLX, and PCVX Headlines

Recent News About These Companies

Australia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plunge

August 28 at 9:44 AM | msn.com

Telix shares just crashed 24%! Here's why

August 28 at 9:44 AM | msn.com

US FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancer

August 27 at 9:58 PM | reuters.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - What's Next?

August 27 at 1:19 PM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

August 27 at 10:00 AM | prnewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

August 26 at 4:22 PM | globenewswire.com

Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference

August 26 at 7:00 AM | globenewswire.com

FY2027 EPS Estimate for Telix Pharmaceuticals Cut by Analyst

August 26 at 2:16 AM | marketbeat.com

Wedbush Reduces Earnings Estimates for Telix Pharmaceuticals

August 26 at 2:21 AM | americanbankingnews.com

Q3 EPS Estimate for Telix Pharmaceuticals Reduced by Analyst

August 26 at 2:11 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

August 25 at 12:26 PM | globenewswire.com

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

August 25 at 3:20 AM | prnewswire.com

FY2028 Earnings Estimate for TLX Issued By Wedbush

August 24, 2025 | marketbeat.com

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

August 23, 2025 | globenewswire.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Q2 2025 Earnings Call Transcript

August 23, 2025 | insidermonkey.com

What is Wedbush's Estimate for TLX FY2028 Earnings?

August 23, 2025 | americanbankingnews.com

Telix Pharmaceuticals (NASDAQ:TLX) Sets New 52-Week Low - What's Next?

August 22, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

August 22, 2025 | prnewswire.com

Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX

August 21, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

August 21, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Should You Buy?

August 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STOK, ADMA, TLX, and PCVX Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.38 +0.13 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$17.22 -0.16 (-0.92%)

As of 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Vaxcyte NASDAQ:PCVX

$30.77 +0.22 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$30.75 -0.02 (-0.06%)

As of 04:44 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Stoke Therapeutics NASDAQ:STOK

$19.77 +0.47 (+2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$19.85 +0.08 (+0.40%)

As of 06:57 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$10.15 -1.95 (-16.12%)

Closing price 04:00 PM Eastern

Extended Trading

$10.22 +0.07 (+0.69%)

As of 07:58 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time